Answers are grounded in this paper and cite their sources.
Spinal cord injury (SCI) is a severe traumatic disease of the central nervous system (CNS), encompassing primary injury and secondary injury, and frequently results in severe neurological dysfunction. During secondary injury, inflammatory responses and apoptosis are interrelated and important pathological processes, accompanied by multiple forms of regulated cell death (RCD), including pyroptosis, necroptosis, and ferroptosis. Inflammatory cells and the various mediators they release can activate complex signaling networks within the injury microenvironment, affecting the survival of neurons and glial cells as well as multiple RCD processes; conversely, apoptotic cells and their clearance status can also feedback-regulate the extent and duration of inflammatory responses, with these two processes exhibiting pronounced phase-dependent and microenvironment-dependent characteristics. Current research has progressively uncovered the molecular basis and spatiotemporal features of the crosstalk between inflammation and apoptosis, yet many unresolved questions remain regarding cell-type specificity, causality, and therapeutic targets. This article systematically summarizes the inflammatory cell composition, key mediators, and signaling pathways in the SCI microenvironment, as well as the molecular mechanisms and cell-type specificity of apoptosis, with a focus on the bidirectional regulation between inflammation and apoptosis and its dynamic changes across different injury phases, while appropriately addressing the intersection of other RCD forms with inflammatory networks. By distinguishing among in vitro experiments, SCI animal studies, bioinformatic analyses, and human studies, this article reviews potential therapeutic strategies related to the inflammation–apoptosis intersection and the difficulties in their clinical translation, and clarifies that findings from non-SCI models primarily provide indirect mechanistic support and cannot be directly used to establish SCI-specific mechanisms or clinical efficacy. On this basis, the potential value of precise phase-specific intervention and multi-target combination therapy is further explored, and the necessity of conducting SCI-specific mechanistic validation and clinical evaluation is emphasized. This review aims to provide a theoretical basis for the mechanistic dissection of SCI secondary injury, the screening for candidate therapeutic targets, and translational research.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: